Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma Inc is developing a range of cannabinoid-based formulations aimed at treating several conditions, notably Alzheimer's disease, with investigational drugs like IGC-AD1 demonstrating significant promise in preclinical studies. The company has raised its valuation based on a net present value (NPV) analysis, indicating substantial upside potential from the current share price. Additionally, anticipated positive data and progress in ongoing research are expected to act as catalysts for further stock performance.

Bears say

The financial outlook for IGC Pharma Inc remains negative primarily due to a consistent net loss of $1.6 million, equating to earnings per share of $(0.02), which aligns with recent consensus estimates but highlights ongoing financial challenges. Significant risks threaten the company's future, including balance sheet and liquidity concerns, potential failures of investigational drug candidates in clinical trials, and difficulties in obtaining necessary regulatory approvals. Additionally, broader macroeconomic factors, competitive pressures, and shifts in investor sentiment towards biotech stocks further complicate IGC Pharma's ability to achieve financial stability and growth.

IGC has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 2 analysts, IGC has a Strong Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.